Get the Stockscreener App
1.76
1.73%
0.03
Pre-market:
1.77
0.01
+0.57%
Inovio Pharmaceuticals Inc stock is traded at $1.76, with a volume of 2.35M.
It is up +1.73% in the last 24 hours and down -14.56% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$1.73
Open:
$1.72
24h Volume:
2.35M
Relative Volume:
1.76
Market Cap:
$120.92M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-0.289
EPS:
-6.09
Net Cash Flow:
$-124.69M
1W Performance:
-18.14%
1M Performance:
-14.56%
6M Performance:
-16.59%
1Y Performance:
-1.12%
1-Day Range:
$1.681
$1.77
1-Week Range:
$1.681
$2.365
52-Week Range:
$1.30
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.76 | 118.86M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Inovio drops as respiratory papillomatosis asset denied accelerated review - MSN
Jefferies reiterates Hold on Inovio stock amid FDA review uncertainty By Investing.com - Investing.com Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio ... - Bluefield Daily Telegraph
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc.INO - FinancialContent
Inovio stock plummets 25% after FDA denies accelerated review for lead drug candidate - The Business Journals
INOVIO’s DNA therapy for rare throat disease gets FDA review - Indian Pharma Post
Inovio Pharmaceuticals stock steady as FDA accepts BLA for INO-3107 - Investing.com Canada
FDA setback gives Inovio a headache - The Pharma Letter
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Why Is Inovio Pharma Stock Sinking Monday?Inovio Pharmaceuticals (NASDAQ:INO) - Benzinga
Inovio (INO) Shares Plummet 21% After FDA Review Update - GuruFocus
Inovio stock tumbles after FDA questions accelerated approval path By Investing.com - Investing.com Australia
Inovio stock tumbles after FDA questions accelerated approval path - Investing.com India
INOVIO (INO) Seeks Accelerated Approval for INO-3107 from FDA - GuruFocus
INOVIO Pharmaceuticals, Inc. Announces FDA Acceptance of BLA for INO-3107 - TradingView — Track All Markets
FDA accepts INOVIO’s BLA for RRP treatment, sets October 2026 target date - Investing.com UK
FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) - PR Newswire
INOVIO Issues Equity Award to New Hire as It Rebuilds for Its Next Act - MyChesCo
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc Stock Analysis and ForecastSwing Trading Watchlist & Get in Early on the Next Big Stock Surge - earlytimes.in
INO (Inovio Pharmaceuticals) EV-to-OCF : -1.30 (As of Dec. 22, 2025) - GuruFocus
Sentiment Review: Is AMODW stock attractive for long term wealth buildingGap Down & Expert Approved Momentum Ideas - moha.gov.vn
Published on: 2025-12-22 07:17:12 - moha.gov.vn
INOVIO Advances Toward First Commercial Product as BLA Filing Caps Pivotal Quarter - MSN
Why retail investors pile into Inovio Pharmaceuticals Inc. stockGap Up & Long-Term Growth Plans - Улправда
Published on: 2025-12-21 00:43:45 - Улправда
INOVIO Reports Inducement Grant Under Inducement Plan - Finviz
Why analysts remain bullish on Inovio Pharmaceuticals Inc. stockIPO Watch & High Return Trade Guides - Улправда
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
How buyback programs support Inovio Pharmaceuticals Inc. (GBM) stockBond Market & Community Consensus Stock Picks - Улправда
Published on: 2025-12-19 20:43:13 - Улправда
Why Inovio Pharmaceuticals Inc. (GBM) stock trades below fair valueQuarterly Market Review & Detailed Earnings Play Strategies - Bölüm Sonu Canavarı
Will Inovio Pharmaceuticals Inc. stock deliver long term returnsPortfolio Performance Summary & Free Safe Entry Trade Signal Reports - DonanımHaber
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Is Inovio Pharmaceuticals Inc. (GBM) stock a top dividend aristocrat candidate2025 Technical Overview & Accurate Intraday Trading Signals - Улправда
Aug Spikes: Can Inovio Pharmaceuticals Inc. (GBM) stock attract analyst upgradesJuly 2025 News Drivers & AI Based Buy and Sell Signals - Улправда
Inovio Pharmaceuticals (STU:GBM) EV-to-OCF : -1.26 (As of Dec. 17, 2025) - GuruFocus
INOVIO’s Future: Investor Insights - StocksToTrade
Inovio Pharmaceuticals (NASDAQ:INO) Stock Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Inovio Pharmaceuticals Earnings Notes - Trefis
How Inovio Pharmaceuticals Inc stock reacts to oil prices2025 Pullback Review & Reliable Trade Execution Plans - moha.gov.vn
JANUS HENDERSON GROUP PLC Expands Stake in Inovio Pharmaceuticals Inc - GuruFocus
Inovio Pharmaceuticals Inc (HAM:GBM) Stock News, Headlines & Updates - GuruFocus
Inovio Pharmaceuticals Inc (HAM:GBM) Stock HoldersInstitutional & Insider Ownership - GuruFocus
INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025) - ts2.tech
Inovio Pharmaceuticals (NASDAQ:INO) Shares Pass Above 200-Day Moving AverageTime to Sell? - MarketBeat
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Will Inovio Pharmaceuticals Inc. stock see insider buying2025 Market Trends & Weekly Watchlist for Hot Stocks - Newser
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):